Exceptional Response to Short-course 177 Lu-PSMA Radioligand Therapy in a Patient With Metastatic Hormone-sensitive Prostate Cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 42007836.
- Also identified by DOI 10.1097/RLU.0000000000006452.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report a 69-year-old man with de novo high-volume metastatic hormone-sensitive prostate cancer (mHSPC) presenting with PSA 433.75 ng/mL and widespread skeletal and nodal metastases. Androgen-deprivation therapy with goserelin, abiraterone, and cyproterone acetate reduced PSA to 44.29 ng/mL. He subsequently received 3 cycles of 177 Lu-PSMA radioligand therapy, achieving a near-complete biochemical response (PSA 0.15 ng/mL) and resolution of bone pain. Nine-month follow-up 99m Tc-PSMA demonstrated complete regression of metastatic lesions. This case highlights the potential efficacy and safety of early 177 Lu-PSMA therapy in high-volume mHSPC, suggesting a role for optimizing hormonal therapy outcomes.
Medical subject headings
- Prostatic Neoplasms
- Lutetium
- Radioisotopes
- Oligopeptides